EXELIXIS INC
EXELIXIS INC
Acción · US30161Q1040 · EXEL · 936718 (XNAS)
Resumen Indicadores financieros
43,00 USD
1,90 % 0,80 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 23:58

Cotizaciones actuales de EXELIXIS INC

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
EXEL
USD
06.06.2025 23:58
43,00 USD
42,37 USD
+1,49 %
XLON: London
London
0IJO.L
USD
06.06.2025 15:07
42,86 USD
42,37 USD
+1,16 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % -0,58 % 16,66 % 12,54 % 20,04 % 95,90 % 92,22 %

Perfil de la empresa para EXELIXIS INC Acción

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Fondos invertidos

Los siguientes fondos han invertido en: EXELIXIS INC invertido:

Fondo
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millones
210,29
Porcentaje (%)
0,49 %

Datos de la empresa

Nombre EXELIXIS INC
Empresa Exelixis, Inc.
Símbolo EXEL
Sitio web https://www.exelixis.com
Mercado principal XNAS NASDAQ
WKN 936718
ISIN US30161Q1040
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Michael M. Morrissey Ph.D.
Capitalización de mercado 9 Mrd.
País Estados Unidos de América
Moneda USD
Empleados 1,3 T
Dirección 1851 Harbor Bay Parkway, 94502 Alameda
Fecha de OPV 2007-10-01

Símbolos de cotización

Nombre Símbolo
Frankfurt EX9.F
London 0IJO.L
NASDAQ EXEL
XETRA EX9.DE

Otras acciones

Los inversores que tienen EXELIXIS INC también tienen las siguientes acciones en su cartera:
ADOBE INC
ADOBE INC Acción
AMAZON.CO INC
AMAZON.CO INC Acción
AMGEN INC
AMGEN INC Acción
CISCO SYSTEMS INC
CISCO SYSTEMS INC Acción
DZ BANK IS.A2535 VAR
DZ BANK IS.A2535 VAR Bono
FÜRST FUGGER PRIVATBANK WACHSTUM
FÜRST FUGGER PRIVATBANK WACHSTUM Fondo
INTEL CORP
INTEL CORP Acción
INTUITIVE SURGICAL INC
INTUITIVE SURGICAL INC Acción
MICRON TECHNOLOGIESLOGY INC
MICRON TECHNOLOGIESLOGY INC Acción
MICROSOFT CORP
MICROSOFT CORP Acción
NVIDIA CORP
NVIDIA CORP Acción
SALESFORCE.CO INC
SALESFORCE.CO INC Acción
STONEX GROUP INC
STONEX GROUP INC Acción
TRANSLATE BIO INC
TRANSLATE BIO INC Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025